Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study

Ítems similars

• Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
  per: Gupta, Neeraj, et al.
  Publicat: (2020)
• The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
  per: Tugnait, Meera, et al.
  Publicat: (2018)
• Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
  per: Neeraj Gupta, et al.
  Publicat: (2022-05-01)
• Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
  per: Tugnait, Meera, et al.
  Publicat: (2019)
• Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option
  per: Ricciuti, Biagio, et al.
  Publicat: (2019)